Mode
Text Size
Log in / Sign up
N/A Completed N=147 Diagnostic

In-Clinic and Home-Use Study of a New Blood Glucose Monitoring System

Source: ClinicalTrials.gov NCT00803777 ↗
Enrolled (actual)
147
Serious AEs
0.0%
Results posted
Jun 2010
Primary outcomePrimary: Number of Duplicate Capillary Results Within +/- 15mg/dL or +/- 20% of Laboratory Glucose Method — 142; 143 number of capillary results (n=79x2)

Summary

The purpose of this study is to evaluate the performance and acceptability of a new blood glucose meter.

Outcome Measures

OutcomeResultp-value
PRIMARY
Number of Duplicate Capillary Results Within +/- 15mg/dL or +/- 20% of Laboratory Glucose Method
142; 143 —
PRIMARY
Number of Duplicate Subject BGM Results Within +/- 15mg/dL or +/- 20% of Healthcare Professional Capillary Results
277 —
SECONDARY
Numbers of BG Results in Zones of the Parkes Error Grid of Clinical Significance of Inaccuracies
146; 11; 1; 0; 0 —
SECONDARY
Number of Participants Rated as <=2 (Labeling Comprehension)
147; 137; 146; 144; 135 —
SECONDARY
Average Within Replicate Coefficient of Variation CV (Precision)
5.9; 7.2 —

Eligibility Criteria

Inclusion Criteria

  • Type 1 diabetes
  • Age 4 to 24 years
  • Routinely performs blood glucose testing at home, at least 2 times per day, for one month or more before enrollment
  • Has used a handheld game system to play video games within a year of enrollment
  • If above age 18, subject is able to speak, read, and understand English. If below age 18, subject's parent/guardian is able to speak, read, and understand English, and is able to provide appropriate supervision.
  • Is willing to complete all study procedures, with appropriate parent/guardian supervision

Exclusion Criteria

  • Hemophilia or any other bleeding disorder
  • Taking prescription anticoagulants (such as Warfarin or heparin) or has clotting problems that may prolong bleeding. Taking Plavix or aspirin daily is not excluded
  • Infection with a blood borne pathogen (e.g., HIV, hepatitis)
  • Subject or parent/guardian is employee of competitive medical device company
  • Cognitive disorder or other condition, which in the opinion of the investigator, would put the person at risk or seriously compromise the integrity of the study
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT00803777). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.

Back to search